Celltrion USA is excited to announce the U.S. debut of its denosumab biosimilars, STOBOCLO® and OSENVELT® (denosumab-bmwo), offering innovative and powerful new solutions for osteoporosis and bone health management
Browsing: Biopharmaceuticals
Exciting news from Lipocine Inc.! The company has just unveiled a groundbreaking license and supply agreement for its innovative testosterone replacement therapy, TLANDO®, in Brazil. This strategic partnership is set to broaden access to this vital treatment across the Brazilian market, significantly boosting Lipocine’s presence on the global stage.
4Moving Biotech has secured a €7.6 million grant from France 2030 to advance its innovative, first-in-class disease-modifying drug for osteoarthritis. This funding will support the company’s efforts to transform treatment options for this widespread condition.